Creative Biolabs Blog

Menu

Skip to content
  • Drug Discovery Research
  • Immunotherapy Research
  • Antibody Engineering Research

Industry Leader

With extensive experience, Creative Biolabs aims to offer you the best in the field of antibody

De Novo Antibody Sequencing

Antibody Sequencing Service Supports Your Antibody Engineering with All-around Service System.

Global Market

Creative Biolabs serves customers from the USA, Canada, European countries and more

Single Domain Antibody

Single domain antibody—the most promising antibody in disease diagnosis, genetic modification and more

08Aug/17

Signal, Migration and Survival of CAR T Cells

August 8, 2017Immunotherapy Researchcar t establish, CAR-T, CAR-T therapybiolabs

CAR-T, Chimeric AntigenReceptor T-Cell Immunotherapy, is the most effective treatment of malignant tumors. Similar to other immunotherapy, its basic principle is to remove cancer cells in the use of the patient’s ownRead More…

08Aug/17

A New Immunotherapy Called CAR-T Will Beat Cancer Surprisingly

August 8, 2017Immunotherapy ResearchCAR T scFV, CAR-Tbiolabs

CAR-T (Chimeric Antigen Receptor T-Cell), as an immunocytotherapy regimen, has attracted a lot of attention from academics, doctors, patients, and investors worldwide. What does make it so attractive and popular? CAR-T modifiesRead More…

07Aug/17

Membrane Protein Overview

August 7, 2017Antibody Engineering ResearchAntibody Discovery, channel protein, gpcr, membrane protein, membrane protein antibody, transport proteinbiolabs

Structural Classification of Membrane Proteins Membrane proteins represent about a third of the proteins in living organisms. Based on their structure, there are main three types of membrane proteins: the first oneRead More…

26Jul/17

A Quick View of the Global R&D Situation of EGFR Drugs

July 26, 2017Antibody Engineering Researchantibody drug, biosimiar, drug patent, egfr-targeted drug, Therapeutic Antibodybiolabs

1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total. Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan,Read More…

24Jul/17

The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!

July 24, 2017Immunotherapy Research, NewsCAR-T, FDA, immunotherapy drug, Novartisbiolabs

Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…

22Jun/17

Will the First CAR-T Therapy Be Approved on July 12? —Novartis CTL019

June 22, 2017Immunotherapy Research, NewsCAR-T, CAR-T therapy, CTL019, Novartisbiolabs

On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluateRead More…

16Jun/17

Best Selling Anti-tumor Drugs in the Next 5 Years

June 16, 2017Antibody Engineering Research, Newsanti-tumor drug, Antibody, monoclonal antibody, Therapeutic Antibodybiolabs

According to the Journal of the American Medical Association, there were 15.4 million cancer patients worldwide in 2013. Among them, the cancer mortality rate in developing countries was higher than that ofRead More…

31May/17

Antibody Diversity

May 31, 2017Antibody Engineering ResearchAntibody, antibody development, Antibody Discovery, antibody isotypes, antibody librariesbiolabs

Before we start to introduce the principle of antibody diversity, you’d better learn about structure of antibody. Antibody consists of two heavy chains and two light chains. Most antibody related research isRead More…

15May/17

Prediction of the Top 10 Best Selling Drugs in 2017 (II)

May 15, 2017Antibody Engineering Research, Newsrecombinant antibody, Therapeutic Antibodybiolabs

Let’s see the other five Top 10 Best Selling drugs ranking from 6th to 10th. 6. Trastuzumab Trastuzumab (trade name: Herceptin) is a humanized monoclonal antibody. It targets HER2, blocks the functionRead More…

05May/17

CAR-T’s Era Is Really Coming!

May 5, 2017Immunotherapy ResearchB-ALL, CAR-T, CD19biolabs

On March 29, 2017, Novartis announced that the US FDA has issued a priority review for its CAR-T therapy CTL019 (tisagenlecleucel-T) biologics licensing application. The indications of CTL019 was recurrent or refractoryRead More…

Posts navigation

  • « Previous
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 17
  • Next »

Categories

  • Antibody Engineering Research
  • Biological Knowledge
  • Drug Discovery Research
  • Immunotherapy Research
  • News

Recent Posts

  • Scientists identify a special gene that produces key antibodies in large quantities
  • The molecular mechanism by which special antibodies protect the body against HIV infection
  • Multispecific antibodies enhance cancer immunotherapy
  • Scientists have cracked HIV’s new way of entering the host cell nucleus, which may lead to new therapeutic drugs
  • Antibody sequencing provides a new path for antibody therapy research

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Drug Discovery Research
  • Immunotherapy Research
  • Antibody Engineering Research